Walsby et al. evaluated the anti-neoplastic potential of CDKI-73 together with fludarabine in CLL and found decreased MCL1 gene expression after CDK9 inhibition while fludarabine had the opposite effect. The gene discussed is CDK9; the disease is B-cell chronic lymphocytic leukemia.